Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

293
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
293
Gut-Brain Axis01:22

Gut-Brain Axis

82
The gut–brain axis is a bidirectional communication system that connects the gastrointestinal tract and the brain. This interaction is mediated through multiple pathways, including the vagus nerve, hormonal signals, immune responses, and chemical messengers produced by gut microbes.Microbial Contributions to Brain FunctionGut microbiota contributes significantly to brain function by producing neuroactive compounds. These include neuroactive compounds that influence neurotransmitters such...
82
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

399
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
399
Regulation of Food Intake01:30

Regulation of Food Intake

3.2K
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
3.2K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

19.8K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
19.8K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

1.3K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How does survodutide work? Plain language review of a potential new medication for obesity and liver disease.

Therapeutic advances in gastroenterology·2026
Same author

Leadership in Obesity Care: Strategies to Support Healthcare Professionals in Effective Decisions, Communication, and Solutions - A Scoping Review.

Journal of healthcare leadership·2026
Same author

Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5.

Journal of endocrinological investigation·2026
Same author

Diabetes management in people undergoing metabolic-bariatric surgery: A guideline from the Joint British Diabetes Societies for Inpatient Care (JBDS-IP) Group.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same author

Unveiling the Potential of Functional Components in Hull-Less Barley Grains: Health Benefits, Structural Composition, and Genetic Advancements.

Foods (Basel, Switzerland)·2026
Same author

Retraction notice to "Advances in biodegradable materials: Degradation mechanisms, mechanical properties, and biocompatibility for orthopedic applications" [Heliyon 10 (2024) e32713].

Heliyon·2025

Related Experiment Video

Updated: Apr 9, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.4K

Targeting Multiple Gut-Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy.

Alexander D Miras1,2, Muzamil Hussain1

  • 1School of Medicine Ulster University Derry UK.

Obesity Science & Practice
|April 8, 2026
PubMed
Summary
This summary is machine-generated.

Obesity treatment can combine gut hormone analogs and naltrexone/bupropion (NB-ER) to target the gut-brain axis. This approach addresses multiple pathways for improved weight management in patients.

Keywords:
GLP‐1neuropharmacologyobesity management medicationweight management

More Related Videos

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.9K
Control of Eating Behavior Using a Novel Feedback System
04:48

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

11.8K

Related Experiment Videos

Last Updated: Apr 9, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.4K
An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.9K
Control of Eating Behavior Using a Novel Feedback System
04:48

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

11.8K

Area of Science:

  • Metabolic and Neural Regulation
  • Obesity Pathophysiology

Background:

  • Obesity is an energy dysregulation disease involving complex metabolic, hormonal, and neural interactions.
  • The "gut-brain axis" describes the interconnectedness of these factors influencing energy balance.

Purpose of the Study:

  • To review clinical evidence on eating behavior changes with gut hormone analogs and NB-ER.
  • To explore the mechanistic rationale for combining these medications to target the gut-brain axis.
  • To identify treatment strategies for patients not achieving goals with single medications.

Main Methods:

  • Review of clinical evidence on physiological and behavioral changes.
  • Analysis of mechanistic pathways targeted by gut hormone analogs and NB-ER.
  • Examination of the gut-brain axis and its role in energy homeostasis and reward.

Main Results:

  • Gut hormone analogs (liraglutide, semaglutide, tirzepatide) target GLP-1 and GIP receptors, impacting the hypothalamus and brainstem to reduce energy intake.
  • Evidence on the effects of gut hormone analogs on the reward system is inconsistent.
  • Naltrexone/bupropion extended-release (NB-ER) targets hypothalamic and mesolimbic systems, reducing food intake and reward-based eating.

Conclusions:

  • Gut hormone analogs and NB-ER have distinct yet complementary effects on gut-brain pathways.
  • These complementary effects provide a mechanistic rationale for combining these agents in obesity treatment.
  • Combined therapy may offer a more comprehensive approach to managing obesity by targeting satiety, hunger, and reward pathways.